Published in J Immunol on March 15, 2008
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog (2010) 1.27
PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology (2010) 1.21
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (2015) 1.19
Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol (2009) 1.18
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol (2012) 1.07
Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World J Gastroenterol (2009) 1.07
PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma. Immunol Cell Biol (2010) 1.07
Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis (2011) 1.05
CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev (2010) 1.04
Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology (2010) 1.02
PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin Immunol (2013) 1.01
Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses. Vaccine (2011) 0.98
Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology (2009) 0.96
Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis. J Immunol (2010) 0.95
Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol (2011) 0.94
Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One (2011) 0.93
Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol (2011) 0.93
Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection. Viral Immunol (2010) 0.91
Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol (2015) 0.87
Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun (2008) 0.87
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. PLoS One (2013) 0.86
The role of innate immunity in HBV infection. Semin Immunopathol (2012) 0.85
Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. J Biomed Biotechnol (2010) 0.82
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity. Mol Ther Nucleic Acids (2013) 0.82
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget (2016) 0.81
A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet (2015) 0.80
Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One (2013) 0.80
Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol (2015) 0.78
Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity - The ANRS-EP38-IMMIP Study. PLoS One (2015) 0.77
Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. PLoS One (2014) 0.77
Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol (2015) 0.76
CD4(+) and CD8(+) T Cell Activation in Children with Hepatitis C. J Pediatr (2015) 0.75
Metabolic regulation of immune responses: therapeutic opportunities. J Clin Invest (2016) 0.75
Boceprevir and personalized medicine in hepatitis C virus infection. Pharmgenomics Pers Med (2012) 0.75
Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. Int J Mol Sci (2017) 0.75
CD56(bright) NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. J Leukoc Biol (2017) 0.75
Interferon-α-induced CD100 on naïve CD8(+) T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction. J Int Med Res (2017) 0.75
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med (2009) 8.06
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med (2005) 1.93
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. Crit Care Med (2008) 1.74
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med (2007) 1.66
Relationship between surgeon volume and adverse outcomes after RYGB in Longitudinal Assessment of Bariatric Surgery (LABS) study. Surg Obes Relat Dis (2009) 1.63
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology (2013) 1.56
Preload responsiveness is associated with increased interleukin-6 and lower organ yield from brain-dead donors. Crit Care Med (2009) 1.53
Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl (2003) 1.44
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Physicians encouraging colorectal screening: a randomized controlled trial of enhanced office and patient management on compliance with colorectal cancer screening. Arch Intern Med (2009) 1.41
Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology (2012) 1.41
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. PLoS One (2007) 1.39
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36
Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 1.36
Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33
Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis (2006) 1.31
Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology (2003) 1.30
Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl (2006) 1.29
Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Sample size for two-stage studies with maintenance therapy. Stat Med (2009) 1.24
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest (2010) 1.21
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol (2008) 1.17
Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology (2011) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem (2013) 1.13
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol (2008) 1.11
Weighted Kaplan-Meier estimators for two-stage treatment regimes. Stat Med (2010) 1.11
Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol (2007) 1.08
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology (2009) 1.04
Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2011) 1.02
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99
Liver and intestine transplantation. Am J Transplant (2004) 0.97
HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res (2011) 0.97
Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog (2013) 0.97
Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl (2002) 0.96
Changing compliance to the American College of Gastroenterology guidelines for the management of variceal hemorrhage: a regional survey. Am J Gastroenterol (2004) 0.96
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J Hepatol (2013) 0.96
Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog (2010) 0.96
Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One (2010) 0.95
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol (2012) 0.95
Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology (2013) 0.95
Weighted log-rank statistic to compare shared-path adaptive treatment strategies. Biostatistics (2012) 0.95
Genetic markers of IgG influence the outcome of infection with hepatitis C virus. J Infect Dis (2008) 0.95
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning. J Clin Psychiatry (2014) 0.94
Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol (2006) 0.94
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci (2011) 0.94
Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One (2011) 0.93
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93
Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol (2013) 0.92
Basic concepts in transplant immunology. Liver Transpl (2005) 0.92
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos (2011) 0.92
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl (2012) 0.91
Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg (2002) 0.90
Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg (2011) 0.90
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Prevalence of adverse intraoperative events during obesity surgery and their sequelae. J Am Coll Surg (2012) 0.90
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology (2006) 0.89
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials (2011) 0.89
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology (2009) 0.89
Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl (2006) 0.89
Up-front versus sequential randomizations for inference on adaptive treatment strategies. Stat Med (2012) 0.88
Innate immune function in placenta and cord blood of hepatitis C--seropositive mother-infant dyads. PLoS One (2010) 0.88
Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85
Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology (2005) 0.84
Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med (2014) 0.83
Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. Clin Immunol (2009) 0.83